Perbandingan Nilai Agregasi Trombosit Pada Pasien Hipertensi Yang Diberi Aspirin Dan Tidak Diberi Aspirin Di Rsup. Prof. Dr. R. D. Kandou Manado

: Thrombocyte hyperaggregation occurs in hypertensive patients. Thrombocyte accumulates and thrombi formation caused by hyperaggregation are important factors in pathogenesis of cardiovaskular and cerebrovascular disease. Around 50 million people consume aspirin everyday to treat or to prevent cardiovascular or cerebrovascular disease. The use of aspirin known can increase bleeding risk especially when trauma occurs or intraoperative, but inhypertensive patients50 or over 50 years old, the benefit of aspirin can be greater then the bleeding risk it carries. Method: This study used comparative study, which compared thrombocyte aggregation value in hypertensive patients with aspirin and without aspirin. The tools that used for thrombocyte aggregation examination is an aggregometer and the data analysis is done by using SPSS software. Result: The difference value of thrombocyte aggregation in hypertensive patients with aspirin and without aspirin used T 2 independent samples test gave significant for ADP 10 µM and 5 µM(p <0.05), respectively 0.001 and 0.01. Conclusion: There is a difference between thrombocyte aggregation value in hypertensive patients with aspirin and without aspirin. Mean value ofthrombocyte aggregation in hypertensive patients with aspirin is lower than hypertensive patients without aspirin